Clinical Trial Detail

NCT ID NCT02923986
Title Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bio-Path Holdings, Inc.
Indications

chronic myeloid leukemia

acute myeloid leukemia

myelodysplastic syndrome

Therapies

BP1001 + Dasatinib

Age Groups: adult senior

No variant requirements are available.